Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a contract with a San Francisco-area based biotech company. The contract amount is €384,000 (eq. $ 524,500).
MEDIAN Technologies will provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer. Within the framework of the study, imaging data will be acquired from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a "first patient in" forecasted May, 2014. MEDIAN will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.
"We are pleased to start 2014 supporting this important trial for a new, hypoxia-targeted therapy," said Ciaran Cooper, Head of Business Development, Clinical Trials Imaging, North America. "Adding this new biotech client demonstrates that our imaging services bring value not only to major pharmaceutical companies, but to top biotechnology companies as well."